{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=30&q=metastatic+pancreatic",
    "query": {
      "q": "metastatic pancreatic",
      "condition": "Pancreatic Cancer",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 1135,
    "total_pages": 114,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=31&q=metastatic+pancreatic&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=29&q=metastatic+pancreatic&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T17:10:37.604Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03269526",
      "title": "BATs Treatment for Pancreatic Cancer, Phase Ib/II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "EGFR BATs after standard of care chemo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-07-28",
      "completion_date": "2026-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269526"
    },
    {
      "nct_id": "NCT06907043",
      "title": "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "EIK1004-001 (IMP1707-001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eikon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 130,
      "start_date": "2025-04-30",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907043"
    },
    {
      "nct_id": "NCT07829185",
      "title": "Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma (PDAC)"
      ],
      "interventions": [
        {
          "name": "modified FOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Pentamidine 300 MG Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-12",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07829185"
    },
    {
      "nct_id": "NCT00417209",
      "title": "Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Larotaxel (XRP9881)",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2006-12",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417209"
    },
    {
      "nct_id": "NCT00878163",
      "title": "GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage IV Pancreatic Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Diagnostic Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2009-03-31",
      "completion_date": "2027-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Orlando, Florida + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00878163"
    },
    {
      "nct_id": "NCT01169649",
      "title": "Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PANCREAS",
        "Neuroendocrine"
      ],
      "interventions": [
        {
          "name": "MK-2206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-07",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2016-02-18",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169649"
    },
    {
      "nct_id": "NCT00869258",
      "title": "Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer Stage IVA"
      ],
      "interventions": [
        {
          "name": "Gemcitabine, docetaxel, and capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy with gemzar",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2005-06",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00869258"
    },
    {
      "nct_id": "NCT01385956",
      "title": "SOM 230 and Gemcitabine in Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "SOM 230 LAR",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-06",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2020-09-28",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385956"
    },
    {
      "nct_id": "NCT05769959",
      "title": "Study of RO7515629 in Participants With HLA-G Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "RO7515629",
          "type": "DRUG"
        },
        {
          "name": "tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2023-06-15",
      "completion_date": "2024-03-19",
      "has_results": false,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Nashville, Tennessee",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05769959"
    },
    {
      "nct_id": "NCT03043508",
      "title": "Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Genetic Mutation",
        "MEN1"
      ],
      "interventions": [
        {
          "name": "Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2015-04-10",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-10-16T17:10:37.604Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043508"
    }
  ]
}